Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches

Background. Metformin is commonly prescribed to treat polycystic ovary syndrome (PCOS) patients, but in some cases, it may not be effective even at high doses or may cause intolerable side effects. Therefore, recent studies have examined the impact of combining metformin with other antidiabetic medi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of endocrinology 2024-03, Vol.2024, p.9900213-11
Main Authors: Heidarpour, Maryam, Mojarad, Mehrzad, Mazaheri-Tehrani, Sadegh, Kachuei, Ali, Najimi, Arash, Shafie, Davood, Rezvanian, Hassan
Format: Article
Language:English
Subjects:
Antidiabetics
Care and treatment
Dextrose
Diabetes
Diabetes therapy
Drug dosages
Endocrinology
GLP-1 receptor agonists
Glucose
Hormones
Hydroxyprogesterone
Hypoglycemic agents
Insulin
Investigations
Metabolism
Obesity
Ovaries
Overweight
Polycystic ovary syndrome
Review
Stein-Leventhal syndrome
Systematic review
Type 2 diabetes
Ultrasonic imaging
Women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Metformin is commonly prescribed to treat polycystic ovary syndrome (PCOS) patients, but in some cases, it may not be effective even at high doses or may cause intolerable side effects. Therefore, recent studies have examined the impact of combining metformin with other antidiabetic medications. Methods. A systematic search was performed in Scopus, PubMed, Web of Science, and Embase up to 30 June 2023. All interventional studies that assessed the efficacy of different antidiabetic agents were included. Results. Among the 3488 records found in the primary search, 16 papers were included. Our study showed that dipeptidyl peptidase-4 inhibitors (DPP4i) had the most significant impact on glycemic profile, while thiazolidinediones (TZDs) had the most influence on lipid levels. However, it was observed that patients taking only metformin experienced a greater increase in high-density lipoprotein cholesterol (HDL-C) levels. Glucagon-like peptide-1 receptor agonists (GLP1RAs) effectively modified various anthropometric measurements, such as weight, body mass index, waist circumference, and waist-to-hip ratio. The effects of different antidiabetic drugs on hormone levels were inconclusive, although testosterone levels were more affected by GLP1RA, sodium-glucose cotransporter-2 inhibitors (SGLT2i), and TZDs. None of the combined therapies showed a significant change in blood pressure. Conclusion. Since PCOS is a metabolic disorder, choosing the best combination of antidiabetic drugs in the clinical course of PCOS patients will be very important. Today, it seems that we need a new metabolic approach for better treatment of the metabolic aspects of these patients.
ISSN:1687-8337
1687-8345
DOI:10.1155/2024/9900213